Exanta - Oral Direct Thrombin Inhibitor for the Prevention and Treatment of Venous Thromboembolism

Print

VTE encompasses both DVT and PE and is the third most common cardiovascular disease after heart attack and stroke.
 
«Back | Next»




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development